Switching From Wegovy Injection to Pill: UK Prescribing Guide

Switching from Wegovy injection to pill is a clinically supervised process that requires careful planning rather than a simple dose swap. Both the weekly injection and the daily tablet contain semaglutide, a GLP-1 receptor agonist used for weight management, but they are absorbed differently and their milligram strengths are not directly interchangeable. UK prescribing information provides one defined transition: patients established on the 2.4 mg once-weekly injection may start the 25 mg once-daily tablet one week after their final injection. Anyone considering this change should speak to a qualified prescriber before altering their treatment.

Can You Switch From Wegovy Injections to the Wegovy Pill?

Yes, patients established on the 2.4 mg once-weekly Wegovy injection can switch to the 25 mg once-daily tablet, starting one week after the final injection, but other injection doses require individual clinical assessment.

Yes, some patients can switch from Wegovy injections to the Wegovy pill, but the transition should follow a prescribed treatment plan rather than a self-calculated dose conversion. Both formulations contain the same active ingredient, semaglutide, and both are used for weight management alongside a reduced-calorie diet and increased physical activity. However, the injection and tablet are absorbed differently and their milligram strengths are not directly interchangeable.

The current UK Summary of Product Characteristics (SmPC) gives one specific transition between the two formulations. Patients treated with semaglutide injection 2.4 mg once weekly can be transitioned to semaglutide tablets 25 mg once daily. The tablets can be started one week after the last semaglutide injection.

This is important because it provides a defined route for someone established on the standard 2.4 mg weekly Wegovy injection maintenance dose. For example, if the final 2.4 mg injection is taken on a Monday, the prescribing information allows the daily tablets to begin one week later. Patients should still follow the exact date and instructions given by their prescriber.

The same rule should not automatically be applied to every Wegovy injection dose. The standard injection escalation schedule includes 0.25 mg, 0.5 mg, 1 mg and 1.7 mg before reaching 2.4 mg once weekly. Current UK tablet prescribing information does not provide a simple equivalent tablet dose for each of these lower injection strengths.

Likewise, UK prescribing information now includes a 7.2 mg once-weekly injection option for some adults with obesity where needed, after treatment at 2.4 mg. The specific tablet-switching instruction in the oral SmPC refers to patients treated with the 2.4 mg once-weekly injection. Patients taking 7.2 mg should therefore not assume that the same transition applies without an individual clinical assessment.

The reason for this caution is explicitly addressed in the SmPC. It states that the effect of switching between semaglutide tablets and semaglutide injections cannot easily be predicted, because oral semaglutide has higher variability in absorption than injected semaglutide.^[7][2]

A 25 mg tablet is therefore not simply the oral equivalent of any injection dose based on the number printed on the packaging. Someone taking 1 mg weekly should not calculate a tablet dose mathematically, and someone taking 2.4 mg should not assume that 25 mg is "ten times stronger". The different routes of administration produce different patterns of absorption and exposure.

Anyone considering a switch should complete a clinical review so the prescriber can confirm the current injection dose, treatment response, side effects, other medicines and whether the practical requirements of a daily tablet are suitable.

How the Switch From 2.4 mg Wegovy Injections to 25 mg Tablets Works

Take the final 2.4 mg injection, wait one week, then begin the 25 mg tablet once daily on an empty stomach, following strict fasting and 30-minute post-dose waiting requirements.

For patients established on Wegovy 2.4 mg injections once weekly, the UK SmPC provides a clear transition to Wegovy 25 mg tablets once daily. The tablet can be started one week after the last injection.

The basic sequence is:

• take the final prescribed 2.4 mg Wegovy injection

• wait one week

• start the prescribed 25 mg Wegovy tablet once daily

• follow the oral administration instructions every day

This defined transition is different from starting the Wegovy pill as a completely new semaglutide patient. Someone beginning oral Wegovy without an established 2.4 mg injection regimen would ordinarily start at 1.5 mg once daily, then increase no faster than monthly through 4 mg and 9 mg to 25 mg, with at least one month at each dose level. Patients should not decide for themselves to bypass this escalation schedule simply because they have previously used a different GLP-1 medicine or a lower dose of Wegovy.

The oral 25 mg dose also has very different administration requirements from the weekly injection. Wegovy tablets should be taken once daily on an empty stomach after fasting for at least 8 hours. The tablet should be swallowed whole with a small amount of plain water, up to 120 mL, approximately half a glass. It should not be split, crushed or chewed.

After taking the tablet, patients should wait at least 30 minutes before eating, drinking or taking other oral medicines. Waiting less than 30 minutes can reduce semaglutide absorption. This means someone who found the weekly injection convenient may need to make a significant change to their morning routine after switching.

For example, a patient who normally wakes up, immediately drinks coffee and takes several tablets with breakfast would need to plan around the Wegovy administration instructions. Other oral medicines may also have their own requirements, so timing should be discussed with a prescriber or pharmacist rather than adjusted without advice.

The tablet should be taken as one tablet per day only. The UK SmPC specifically states that patients should not take more than one tablet per day to achieve the effect of a higher dose. Lower-strength tablets should therefore not be combined as a homemade substitute for a prescribed 25 mg tablet.

If a daily tablet dose is missed, the SmPC says the missed dose should be skipped and the next dose taken the following day. Patients should not double the next dose to compensate.

These practical differences are central to a successful switch. The active ingredient remains semaglutide, but treatment changes from a once-weekly injection with flexible meal timing to a once-daily medicine with specific fasting, water and post-dose waiting requirements.

What to Expect After Switching From the Injection to the Pill

Side effects and treatment response may differ after switching because oral semaglutide absorption is more variable than subcutaneous injection, even though both formulations contain semaglutide.

Switching from Wegovy injections to tablets does not mean starting an entirely unrelated medicine. Both formulations contain semaglutide and act as GLP-1 receptor agonists. However, an individual may still notice differences after changing formulation because oral absorption is more variable than absorption from a subcutaneous injection.

The UK SmPC specifically warns that the effect of switching cannot easily be predicted. This is an important limitation. A patient should not expect appetite suppression, side effects or weight change to feel exactly identical from the first day simply because the active ingredient is the same.

Adherence becomes especially important with oral treatment. The prescribing information notes that food and larger volumes of water can reduce absorption, and patients should observe the required fasting period and 30-minute post-dose interval. If treatment response appears lower than expected, the SmPC advises clinicians to be aware of the variability of oral absorption and the importance of following the dosing regimen.

Both formulations share many of the same potential side effects because both contain semaglutide. Common problems include nausea, diarrhoea, constipation and vomiting. The safety profile of the tablets in clinical trials was broadly consistent with the known safety profile of semaglutide injections, although individual experiences vary.

Patients should contact a healthcare professional if side effects are severe, persistent or difficult to manage. Vomiting and diarrhoea can contribute to dehydration, which may be particularly important for people with kidney problems.

Patients should seek urgent medical assessment for persistent, severe abdominal pain, as this may be a symptom of acute pancreatitis. UK safety information for GLP-1 medicines has strengthened warnings concerning acute pancreatitis, including rare serious cases.^[9] Treatment should not simply be continued through severe unexplained abdominal pain without medical advice.

Semaglutide product information also includes an important warning about sudden visual symptoms. Sudden loss of vision, including partial loss of vision, requires urgent ophthalmological assessment because semaglutide has been associated with a very rare risk of non-arteritic anterior ischaemic optic neuropathy, known as NAION.

People with type 2 diabetes may require additional consideration when switching. Semaglutide can lower blood glucose, and the risk of hypoglycaemia may be increased when it is used with medicines such as insulin or sulfonylureas. The oral SmPC advises clinicians to consider reducing concomitant insulin or insulin secretagogue doses when initiating semaglutide where appropriate.

Pregnancy is another important consideration. Semaglutide should not be used during pregnancy and should be discontinued at least two months before a planned pregnancy because of its long half-life.^[1][2]

A switch should therefore include more than issuing a different formulation. The prescriber may need to review side effects, other medicines, diabetes treatment, pregnancy plans and whether the patient can realistically follow the daily tablet routine.

Who Might Consider Switching From Wegovy Injections to Tablets?

Patients established on 2.4 mg weekly injections who prefer oral dosing may consider switching, but the tablet's daily fasting routine makes it less suitable for those who cannot reliably follow strict morning administration requirements.

The Wegovy pill may be attractive to patients who want to continue semaglutide treatment but would prefer not to use a weekly injection. However, being uncomfortable with needles is only one factor in deciding whether to switch.

Someone may wish to discuss the tablet with a prescriber because they:

• experience significant needle anxiety

• dislike self-injecting

• have difficulty using an injection device

• prefer a medicine taken by mouth

• travel frequently and prefer not to manage injection pens

• are already established on 2.4 mg weekly Wegovy and want to discuss the defined 25 mg tablet transition

However, the tablet is not automatically the more convenient option. A person may prefer to remain on the injection if they:

• find once-weekly dosing easier than taking medicine every day

• eat or drink immediately after waking

• cannot reliably complete an 8-hour fast before dosing

• take several important oral medicines first thing in the morning

• prefer the flexibility of an injection that can be taken with or without meals

The weekly injection can be administered at any time of day, with or without food.^[1][8] In contrast, the tablet requires a consistent fasting and timing routine. Someone who frequently forgets daily medicines may therefore find the once-weekly injection easier even if they would theoretically prefer a pill.

Treatment response also matters. A patient doing well on an injection should consider what they hope to gain from switching and discuss the balance with their prescriber. Conversely, someone who is struggling to adhere to injections may find a daily oral option more sustainable if they can follow the administration requirements.

Patients should not switch because of an assumption that the pill is necessarily stronger, weaker or associated with fewer side effects. There has not been a direct head-to-head trial proving that one formulation is universally better for weight loss, and both contain the same active substance. The oral formulation also has greater variability in absorption.

Particular caution is needed for patients who are not currently on 2.4 mg once-weekly semaglutide injections. The explicit UK transition is from 2.4 mg weekly injection to 25 mg daily tablets, beginning one week after the final injection. Current prescribing information does not set out a simple tablet equivalent for each lower injection step or for the 7.2 mg weekly injection dose.

In summary, switching from Wegovy injections to the pill is possible, but it should be treated as a clinically supervised formulation change rather than a self-directed dose conversion. For patients established on 2.4 mg once-weekly semaglutide injections, UK prescribing information provides a defined transition to 25 mg once-daily tablets starting one week after the final injection. Other dose situations require individual assessment.

Anyone considering the change should speak to a qualified prescriber before stopping injections, starting tablets or altering the timing between formulations. The safest plan is one based on the exact current Wegovy dose, treatment history, tolerability, other medicines and ability to follow the daily oral dosing instructions.

Scientific References

1. Wegovy 2.4 mg, FlexTouch solution for injection in pre-filled pen – Summary of Product Characteristics.
2. Wegovy 1.5 mg tablets – Summary of Product Characteristics.
3. First GLP-1 tablet for weight loss approved in the UK.
4. Medicines regulator approves up to 7.2 mg dose of semaglutide (Wegovy) for patients with obesity only.
5. Semaglutide – Drugs. BNF / NICE.
6. Wegovy – opinion on variation to marketing authorisation (oral tablets).
7. Rybelsus – Summary of Product Characteristics (EMA product information).
8. Wegovy – Summary of Product Characteristics (EMA product information).
9. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
10. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines (Ozempic, Rybelsus, Wegovy).
11. First oral GLP-1 treatment for weight management.
12. Efficacy, Safety and PK of Once-Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model-Informed Drug Development Approach.
13. Ocular disorders during treatment with GLP-1 receptor agonists: a systematic review and meta-analysis of observational studies.
14. Optic Ischaemic Neuropathy in Incretin-Based Therapy: A Comparative Analysis of Real-World Safety Data.
15. Semaglutide and risk of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) in type 2 diabetes mellitus: A systematic review and meta-analysis.
16. Effect of Various Dosing Schedules on the Pharmacokinetics of Oral Semaglutide: A Randomised Trial in Healthy Subjects.

Frequently Asked Questions